People who stop using smokeless tobacco after a heart attack may extend their life expectancy similar to people who stop smoking, according to new research in the American Heart Association journal Circulation.
"We didn't expect to see such a strong association among those people who stopped using (smokeless tobacco)," said Gabriel Arefalk, M.D., lead researcher and cardiologist at Uppsala University Hospital in Uppsala, Sweden. "After a heart attack, no doubt smoking cessation reduces the risk of death approximately one third and is really a cornerstone of cardiac rehabilitation worldwide. For smokeless tobacco, we did not know."
This may be the first study to examine the impact of smokeless tobacco on death in heart attack survivors.
Researchers analyzed the effect of quitting the use of snus, a moist Swedish smokeless powder tobacco kept under the upper lip. It's a variant of snuff, but doesn't need to be spit out.
They reviewed data on heart attack survivors younger than 75 in Sweden in 2005-09 and identified 2,474 snus users. Of those, 675 quit using snus. During two years of follow-up, 14 snus-quitters died and 69 of those who continued using snus died. In a mathematical analysis estimating the number of people who die in 1,000 years, researchers determined that the death rate was 9.7 per 1,000 person-years at risk for snus quitters and 18.7 for snus users.
After considering factors like age, gender, other tobacco use, occupation and participation in a cardiac rehabilitation program, researchers said those who stopped using snus had nearly half the mortality risk, similar to the benefit observed with smoking cessation.
Although the study focused on snus, Arefalk said nicotine levels are comparable to levels in snuff.
Snuff use is increasing worldwide. In the largest market, the United States, about 1.7 billion cans are consumed each year. The largest concentration of a population (prevalence) using snuff is in Sweden, where 20 percent of men and 3 percent of women use snus daily.
Co-authors are Kristina Hambraeus, M.D.; Lars Lind, M.D., Ph.D.; Karl Michaelsson, M.D., Ph.D.; Bertil Lindahl, M.D., Ph.D.; and Johan Sundstrom, M.D., Ph.D.
The Swedish Heart-Lung Foundation, Swedish Research Council and Swedish Geriatric Fund supported this study.
Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association's policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at http://www.heart.org/corporatefunding.
For Media Inquiries: (214) 706-1173
Bridgette McNeill contact: (214) 706-1135; firstname.lastname@example.org
Julie Del Barto (broadcast): (214) 706-1330; email@example.com
For Public Inquiries: (800)-AHA-USA1 (242-8721)
heart.org and strokeassociation.org
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.